anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 20,761-20,790
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

20,761-20,790 of 26,550

filter-aware
01
Slide 1
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
02
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
03
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
04
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
05
BenevolentAI | Investor Conference Presentation Deck | 17 slidesBenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
The slide uses a split-screen approach to contrast pre-clinical efficiency with clinical efficacy improvements.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
03
Includes histological images of PRAME expression and a table of prevalence by indication.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem1 hit
04
The slide uses a process flow diagram to show the progression of clinical trial cohorts.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem1 hit
05
The slide uses a process flow diagram to illustrate trial cohorts. Cohorts B and C are greyed out, indicating they are not the focus of this specific update.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · Problem1 hit
06
The slide uses a before-after framework to contrast the focus areas of two clinical trial phases, followed by a numbered list of specific improvements.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
07
The slide uses a process-flow layout to show progression from Phase 1a to 1b to final takeaways.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
08
Includes footnotes defining abbreviations and trial parameters.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
09
Data cut-off date is 06-Sept-2022. Includes footnotes regarding patient outcomes and definitions.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
Data cut-off 06-Sept-2022. Footnotes define ORR and cORR criteria.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
11
The slide uses waterfall charts to visualize clinical trial efficacy across various solid tumor types.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
12
Clinical trial data visualization using spider plots (spaghetti plots) to track individual patient tumor burden changes.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
13
Includes longitudinal persistence data, peak frequency comparison, and tumor infiltration correlation with clinical response (PD/SD vs PR/cPR).Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
14
The chart uses a Mann-Whitney U test to compare the two groups (p=0.076).Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
15
Immatics | Results Presentation Deck | 25 slidesImmatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
16
The table calculates the addressable patient population by filtering total incidence down to R/R incidence, then applying PRAME positivity and HLA-A*02:01+ prevalence.Immatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
Immatics | Results Presentation Deck | 25 slidesImmatics | Results Presentation Deck | 25 slides · Immatics
Conference presentation Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
01
Slide 1
VectivBio | Results Presentation Deck | 9 slidesVectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · Setup1 hit
02
VectivBio | Results Presentation Deck | 9 slidesVectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · Setup1 hit
03
The slide uses a timeline-based study design diagram to illustrate the clinical trial phases.VectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
04
VectivBio | Results Presentation Deck | 9 slidesVectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
05
The chart tracks clinical trial data showing efficacy over time.VectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
06
The chart tracks clinical response defined as >20% PS reduction. Sample sizes decrease from n=9 at month 0 to n=5 at month 6.VectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · EvidenceLoop · Cost Of Inaction1 hit
07
PS likely refers to Parenteral Support.VectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · Key TakeawaysLoop · Voice Of Customer1 hit
08
VectivBio | Results Presentation Deck | 9 slidesVectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · Appendix1 hit
09
The slide includes a disclaimer that the data is not intended to demonstrate comparative efficacy.VectivBio | Results Presentation Deck | 9 slides · VectivBio
Deck Investor relations Beat · Appendix1 hit